Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
40:26
Benefit-Risk Considerations During Drug Product Development (8of14) REdI 2018
1:20:20
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
25:48
GDF2025 - D1S20 - Questions & Panel Discussion - Session Four / Day One Closing
1:56:15
Understanding FDA Inspections and Data
29:42
CMC Considerations for CAR T Cell Product Development
1:29:39
Bench to Bedside Chats: Guidance for Industry CGMP for Phase 1 Investigational Drugs
28:12
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
26:11